Trust Signals
Evidence standard: Every clinical claim is graded by study type (RCT, animal, mechanistic). Speculative claims are labeled.
Conflicts: FormBlends sells research compounds. This page grades tesofensine honestly, including where it loses to approved alternatives.
Regulatory note: Tesofensine is not FDA approved. It is a research compound. This page is educational, not medical advice.
Key Takeaways
- The TIPO-1 phase 2 RCT (n=203, 24 weeks) showed 0.5 mg daily produced a mean of roughly 10.6 kg weight loss versus 2.2 kg on placebo, a real and statistically significant difference.
- Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine), not a peptide and not a GLP-1 agonist. Its mechanism is chemically distinct from semaglutide or tirzepatide.
- The 1 mg dose showed more weight loss but clinically meaningful cardiovascular signals (heart rate and blood pressure elevation), making 0.5 mg the dose studied further.
- No phase 3 RCT exists, no FDA approval exists, and no long-term maintenance data exists. Anyone claiming certainty about 12-month or 2-year results is extrapolating.
- Purity verification matters critically: tesofensine is a dopaminergic compound and underdosed or adulterated material carries both efficacy and safety unknowns.
Direct Answer: What Do Tesofensine Before and After Results Look Like?
In the only phase 2 RCT, tesofensine at 0.5 mg daily produced roughly 10.6 kg of weight loss over 24 weeks, mostly from fat mass, compared to 2.2 kg on placebo. Visible body composition changes are measurable by 8 to 12 weeks. No phase 3 data, no FDA approval, and no long-term maintenance data exist to confirm durability.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is tesofensine and why is it grouped with peptides?
- How does tesofensine produce weight loss? Mechanism with real numbers
- Evidence ledger: what each claim is actually based on
- What does the before and after timeline look like week by week?
- What happens to body composition, not just body weight?
- What most pages get wrong about tesofensine results
- Honest head-to-head: tesofensine vs semaglutide vs phentermine/topiramate
- What adverse effects appear in before and after periods?
- Operational and label literacy: how to read a COA, dose, and spot degraded product
- FAQ
- Sources
- Disclaimers
What Is Tesofensine and Why Is It Grouped With Peptides?
Tesofensine is a phenyltropane-class small molecule originally developed by NeuroSearch for Parkinson's disease and Alzheimer's disease. It is not a peptide. It entered obesity research after incidental weight loss was noted in neurological trials. It circulates alongside research peptides like BPC-157, PT-141, and AOD-9604 because it is purchased through the same research compound channels and discussed in the same clinical forums, not because of any structural similarity.
Its chemical identity is important because it shapes both its mechanism and its risk profile. A triple monoamine reuptake inhibitor carries cardiovascular and psychiatric risks that a GLP-1 receptor agonist peptide does not, and vice versa. Conflating the categories produces misinformed protocols.
How Does Tesofensine Produce Weight Loss? Mechanism With Real Numbers
Tesofensine blocks the reuptake transporters for serotonin (SERT), dopamine (DAT), and norepinephrine (NET). By blocking all three, it raises synaptic concentrations of all three monoamines simultaneously. This produces two convergent effects relevant to weight:
- Appetite suppression: Elevated hypothalamic serotonin and dopamine reduce hunger signaling. In TIPO-1 controlled analyses, estimated caloric intake fell by several hundred kilocalories per day relative to placebo, which accounts for the majority of the observed weight loss.
- Modest thermogenic contribution: Norepinephrine elevation activates beta-adrenergic receptors in adipose tissue. Animal data from Astrup et al. (2008, Lancet) suggests a small increase in energy expenditure, but the magnitude in humans is not quantified with precision in published literature. Extrapolating the animal number to a human clinical effect is speculative.
Tesofensine has an oral bioavailability suitable for once-daily dosing and a half-life long enough to provide consistent coverage without multiple daily doses, based on the TIPO-1 dosing schedule. Precise pharmacokinetic parameters (specific half-life, Tmax) from published human data are not detailed in the Lancet paper; extrapolating exact numbers here would risk fabrication.
Evidence Ledger: What Each Claim Is Actually Based On
| Claim | Best Evidence Type | Source / Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| 0.5 mg produces ~10.6 kg loss in 24 weeks | Phase 2 RCT (n=203) | Astrup et al., Lancet 2008 | Strong positive | Moderate (single phase 2, no phase 3) |
| 1 mg produces greater loss but more CV events | Phase 2 RCT (n=203) | Astrup et al., Lancet 2008 | Positive effect, negative safety signal | Moderate |
| Thermogenic (energy expenditure) contribution | Animal study + mechanism | Rodent data cited in Astrup 2008 | Small positive | Low (not quantified in humans) |
| Fat mass preferentially lost vs lean mass | Phase 2 RCT sub-analysis | TIPO-1 body composition data | Positive | Moderate |
| Weight is maintained long-term after stopping | No data | None published | Unknown | Very Low (mechanistic concern for rebound) |
| Cardiovascular safety at 0.5 mg over years | No data | No long-term RCT | Unknown | Very Low |
| Effective appetite reduction (caloric intake) | Phase 2 RCT controlled feeding | Astrup et al., Lancet 2008 | Positive | Moderate |
What Does the Before and After Timeline Look Like Week by Week?
Based on TIPO-1 data and the known pharmacodynamics of monoamine reuptake inhibition:
- Days 1 to 7: Appetite suppression begins as monoamine levels rise. Dry mouth, mild nausea, and insomnia are most common in this window as the system adjusts.
- Weeks 2 to 4: Caloric deficit accumulates. Early weight changes (1 to 3 kg) become measurable on a scale but are not visible body composition changes for most people.
- Weeks 4 to 12: The steepest phase of weight loss in TIPO-1 occurred here. Mean losses in the 0.5 mg group were tracking ahead of the 24-week average during this window.
- Weeks 12 to 24: Rate of loss typically slows as body weight falls and total energy expenditure adjusts. The plateau dynamic is not unique to tesofensine; it is a feature of any weight loss intervention.
- Beyond 24 weeks: No published RCT data. Extrapolation from other centrally-acting agents suggests continued modest loss or plateau, with rebound risk upon discontinuation.
What Happens to Body Composition, Not Just Body Weight?
TIPO-1 included body composition assessments. The dominant finding was fat mass reduction accounting for the substantial majority of total weight lost. Lean mass was not significantly preserved in absolute terms, meaning some muscle mass was lost, as is typical in any hypocaloric state without resistance training. Relative to the scale of fat loss, lean mass loss was proportionally small.
Tesofensine has no known anabolic mechanism. It does not stimulate muscle protein synthesis or growth hormone secretion. Combining it with resistance training and adequate protein intake to limit lean mass loss is a reasonable protocol, though no RCT has formally tested this combination.
What Most Pages Get Wrong About Tesofensine Results
This is the section most competitor pages omit entirely.
1. They treat one phase 2 trial as if it were approval-level evidence. TIPO-1 was a well-designed RCT, but n=203 over 24 weeks is not a phase 3 program. The effect size is real; the certainty about long-term safety and durability is not.
2. They ignore dose dependency on the risk side. The 0.5 mg and 1 mg doses are treated as interchangeable in many summaries. They are not. The 1 mg dose produced more weight loss but unacceptable cardiovascular signals in the trial. Using higher doses to accelerate results is not supported by evidence and directly contradicts the trial's own safety conclusions.
3. They do not address the purity problem. Tesofensine purchased as a research compound is not manufactured under pharmaceutical GMP. A product labeled 0.5 mg may contain 0.3 mg or 0.8 mg of active material depending on synthesis quality, or may contain process impurities not reflected on a basic COA. This is not a theoretical concern; it is routine in unregulated compound markets. Underdosing produces weak results; overdosing with a dopaminergic compound carries real cardiovascular and behavioral risk.
4. They present "before and after photos" as evidence. Individual photos are not data. They reflect lighting, hydration, posing, and selective presentation. The TIPO-1 trial data is the evidence. Photos are marketing.
5. They do not mention withdrawal dynamics. No published trial has tracked weight trajectories after tesofensine is stopped. Given that the entire mechanism is pharmacologically-mediated appetite suppression, removal of the drug removes the suppression. Weight regain is a predictable concern that is never addressed in promotional content.
Honest Head-to-Head: Tesofensine vs Semaglutide vs Phentermine/Topiramate
| Factor | Tesofensine 0.5 mg | Semaglutide 2.4 mg (Wegovy) | Phentermine/Topiramate (Qsymia) |
|---|---|---|---|
| Best RCT weight loss | ~10.6 kg / 24 weeks (TIPO-1) | ~14.9% body weight / 68 weeks (STEP-1, n=1961) | ~8.6 to 10.2 kg / 56 weeks (CONQUER, n=2487) |
| Evidence level | Phase 2 only, n=203 | Phase 3 program, multiple large RCTs | Phase 3 program, FDA approved 2012 |
| FDA approval | No | Yes (obesity, 2021) | Yes (obesity, 2012) |
| Mechanism | Triple monoamine reuptake inhibitor | GLP-1 receptor agonist | Sympathomimetic + GABA modulator |
| CV safety data | Concerning at 1 mg; limited at 0.5 mg, short term only | Positive CV outcome data (SELECT trial) | Some heart rate increase; no outcome trial |
| Regain on stopping | Expected but unstudied | Documented (STEP-1 extension data) | Documented |
| Access | Research compound or compounding only | Prescription, sometimes insured | Prescription, schedule IV |
| Where tesofensine loses | Evidence base, regulatory standing, long-term safety data, reimbursement. Tesofensine loses on all four dimensions to both comparators. | ||
What Adverse Effects Appear in the Before and After Period?
In TIPO-1, the most common adverse events at 0.5 mg were dry mouth, nausea, constipation, insomnia, and diarrhea. Heart rate increases were measurable at both 0.5 mg and 1 mg, with the 1 mg group showing clinically concerning elevations. Blood pressure increases were also reported, particularly in the 1 mg group.
Psychiatric effects consistent with elevated dopamine and norepinephrine (agitation, anxiety, mood changes) were reported in a minority of participants. Because tesofensine acts on dopaminergic pathways, there is a theoretical dependence concern analogous to other dopamine reuptake inhibitors, though this has not been formally assessed in the published obesity trials.
Operational and Label Literacy: How to Read a COA, Dose, and Spot Degraded Product
What a credible COA must contain:
- HPLC purity result (reputable suppliers show above 98% for active compound)
- Mass spectrometry (MS) identity confirmation matching the molecular formula for tesofensine
- Heavy metals panel (lead, arsenic, mercury, cadmium) with quantitative results, not just "pass"
- Microbiological limits if any non-oral route is considered
- Batch number traceable to a named third-party lab, not an in-house certificate
Dosing math: The TIPO-1 trial used 0.25 mg, 0.5 mg, and 1 mg oral capsules. If purchasing a powder for research, accurately weighing milligram-level quantities requires a calibrated analytical balance with at least 0.1 mg resolution. A standard kitchen milligram scale (resolution 0.001 g) is not accurate enough at this dose range without careful taring and multiple readings.
Storage and stability: Tesofensine as a small molecule is more stable than peptides, but it should be stored away from heat, light, and moisture. Discoloration, clumping, or a change in physical form from the original are signals of degradation or contamination. Unlike peptides, tesofensine does not require cold-chain storage in powder form, but heat exposure above recommended ranges can alter purity.
Why the chemistry matters for rules: Tesofensine does not share the oxidation sensitivity of peptide bonds. It is not degraded by the same pathways as a GLP-1 analog. The rule against co-administering it with other monoaminergic agents (MAOIs, SSRIs, SNRIs) is not about chemical incompatibility in a vial but about pharmacodynamic synergy at the transporter level, risking serotonin syndrome or hypertensive crisis. That is a pharmacology rule, not a formulation rule, and it applies regardless of how the product is sourced.
FAQ
How much weight do people lose with tesofensine before and after 24 weeks?
In the NeuroSearch TIPO-1 phase 2 RCT (n=203), subjects on 0.5 mg daily lost a mean of roughly 10.6 kg versus 2.2 kg on placebo over 24 weeks. The 1 mg group lost roughly 12.8 kg but had a substantially higher rate of cardiovascular and psychiatric adverse events.
Is tesofensine FDA approved?
No. Tesofensine is not FDA approved for any indication as of 2026. It completed phase 2 trials but has not completed a phase 3 program in the United States. It is available only as a research compound or through compounding pharmacies in some jurisdictions.
How does tesofensine cause weight loss mechanistically?
Tesofensine inhibits reuptake of serotonin, dopamine, and norepinephrine (triple monoamine reuptake inhibitor). This increases satiety signaling and, in animal studies, raises energy expenditure. The net clinical effect is reduced caloric intake, estimated at roughly 300 to 500 kcal per day less in controlled feeding data from TIPO-1.
What body composition changes appear in before and after data?
TIPO-1 sub-analyses showed the majority of weight lost was fat mass, with modest lean mass preservation relative to total loss. Tesofensine is not anabolic; lean mass is preserved proportionally, not absolutely, compared to diet alone.
How does tesofensine compare to semaglutide for weight loss?
Semaglutide 2.4 mg weekly (STEP-1 trial, n=1961) produced roughly 14.9% body weight loss over 68 weeks versus placebo. Tesofensine 0.5 mg produced roughly 10.6 kg over 24 weeks. No head-to-head RCT exists. Semaglutide has a larger evidence base, phase 3 data, and FDA approval; tesofensine does not.
What are the main side effects seen before and after starting tesofensine?
The most common adverse events in TIPO-1 were dry mouth, nausea, constipation, insomnia, and elevated heart rate. The 1 mg dose showed clinically meaningful increases in heart rate and blood pressure, which led to dose-range preference for 0.5 mg in subsequent research.
How long does it take to see visible tesofensine results?
In TIPO-1, the majority of weight loss occurred in the first 12 weeks at the 0.5 mg dose. Appetite suppression effects are reported within days of initiation, but visible body composition changes require weeks of sustained caloric deficit.
Can tesofensine be combined with a GLP-1 agonist?
No robust human RCT data exists on combination use as of 2026. The theoretical concern is additive cardiovascular risk from norepinephrine reuptake inhibition combined with the heart rate effects sometimes seen with GLP-1 agonists. Any combination would be off-label and carries unstudied risk.
Is tesofensine a peptide?
No. Tesofensine is a small-molecule phenyltropane derivative, not a peptide. It is often listed alongside peptide weight-loss compounds because it circulates in the same research channels, but its mechanism and chemistry are distinct from peptides like semaglutide or tirzepatide.
What does a tesofensine COA need to show?
A credible COA should include HPLC purity (ideally above 98%), mass spectrometry identity confirmation, absence of heavy metals, microbiological limits if any injectable route is considered, and a verifiable batch number from a named third-party laboratory.
Does weight return after stopping tesofensine?
TIPO-1 did not include a washout follow-up phase long enough to quantify rebound. Mechanistically, withdrawal of monoamine reuptake inhibition removes the appetite-suppressing effect, and weight regain is consistent with what is seen after stopping other centrally-acting anorectic agents. Long-term maintenance data is absent.
Sources
- Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. International Journal of Obesity, 1992. (Background context on monoamine interventions in obesity.)
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. (Primary TIPO-1 RCT.)
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384:989-1002. (Semaglutide comparator data.)
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER). Lancet. 2011;377(9774):1341-1352. (Phentermine/topiramate comparator data.)
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232. (Semaglutide CV outcome data.)
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA.gov. (Regulatory status reference.)
- NeuroSearch. TIPO-1 Clinical Trial Summary Documentation, 2008. (Referenced in Astrup et al. Lancet 2008 supplementary data.)
Disclaimers
Platform: FormBlends is an educational and research compound information platform. Content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance.
Research Compound: Tesofensine is not approved by the FDA or equivalent regulatory agencies for human therapeutic use. Where sold, it is sold strictly for research purposes. It is not intended for human consumption, self-administration, or therapeutic use outside of a clinical research framework supervised by licensed professionals.
Results: Results described on this page reflect clinical trial outcomes under controlled conditions. Individual results will vary. Before and after outcomes depend on diet, activity, baseline health, purity of compound, and numerous other variables not controlled in real-world use.
Trademark: Wegovy is a registered trademark of Novo Nordisk. Qsymia is a registered trademark of Vivus. FormBlends has no affiliation with these companies. Trademarks are used for descriptive comparison only.